BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 31597088)

  • 21. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
    Biernacki MA; Brault M; Bleakley M
    Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploiting natural killer group 2D receptors for CAR T-cell therapy.
    Demoulin B; Cook WJ; Murad J; Graber DJ; Sentman ML; Lonez C; Gilham DE; Sentman CL; Agaugue S
    Future Oncol; 2017 Aug; 13(18):1593-1605. PubMed ID: 28613086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The recent advancement of TCR-T cell therapies for cancer treatment.
    Zhao X; Shao S; Hu L
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
    Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X
    J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor-modified T cells strike back.
    Frigault MJ; Maus MV
    Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T-cell therapy of solid tumors.
    Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
    Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.
    DeRenzo C; Krenciute G; Gottschalk S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():830-837. PubMed ID: 30231350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 37. Overcoming key challenges in cancer immunotherapy with engineered T cells.
    Arcangeli S; Mestermann K; Weber J; Bonini C; Casucci M; Hudecek M
    Curr Opin Oncol; 2020 Sep; 32(5):398-407. PubMed ID: 32796230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CARs in the Lead Against Multiple Myeloma.
    Ormhøj M; Bedoya F; Frigault MJ; Maus MV
    Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.